AR and prostate cancer: This is especially the case in the context of prostate cancer (PCa), where 60% of metastatic castration-resistant PCa (mCRPC) patients harbored more than one gene alteration associated with resistance, expressed in different single cell, like mutations of the androgen receptor (AR) locus 21.